Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An acute myeloid leukemia that is characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.
Biomarker and diagnostic research for core binding factor acute myeloid leukemia has been reported in the published literature.
3 clinical trials registered. Interventions under study include drug therapy and procedural interventions. Pipeline includes 2 PHASE2. Research is primarily sponsored by academic and government institutions.
34 publications have been identified in PubMed for core binding factor acute myeloid leukemia. Research spans Clinical Trial Publication (26%), Basic Science / Preclinical (18%), and Other (15%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 9 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:44 AM UTC
Laboratory research | 6 | 18% |
Other research | 5 | 15% |
Testing and diagnosis research | 5 | 15% |
Disease patterns and progression | 3 | 9% |
Research summaries | 2 | 6% |
Patient case studies | 2 | 6% |
New treatment approaches | 2 | 6% |
Fareed S (2026). [PMID: 39961289](https://pubmed.ncbi.nlm.nih.gov/39961289/). *Oncology*. [Clinical Trial Publication]
Vasseur L (2026). [PMID: 41888395](https://pubmed.ncbi.nlm.nih.gov/41888395/). *Leukemia*. [Diagnostic / Biomarker]
Senapati J (2026). [PMID: 41694734](https://pubmed.ncbi.nlm.nih.gov/41694734/). *Hemasphere*. [Gene Therapy / Novel Therapeutics]
Döhner H (2026). [PMID: 41490515](https://pubmed.ncbi.nlm.nih.gov/41490515/). *Blood*. [Clinical Trial Publication]
Huang J (2026). [PMID: 41689467](https://pubmed.ncbi.nlm.nih.gov/41689467/). *Am J Hematol*. [Gene Therapy / Novel Therapeutics]
Hou B (2026). [PMID: 41452105](https://pubmed.ncbi.nlm.nih.gov/41452105/). *Pediatr Hematol Oncol*. [Clinical Trial Publication]
Azevedo RS (2026). [PMID: 41173347](https://pubmed.ncbi.nlm.nih.gov/41173347/). *Leuk Lymphoma*. [Clinical Trial Publication]
Sheikh IN (2025). [PMID: 39702892](https://pubmed.ncbi.nlm.nih.gov/39702892/). *Pediatr Blood Cancer*. [Other]
Tarantino S (2025). [PMID: 40269277](https://pubmed.ncbi.nlm.nih.gov/40269277/). *Bone Marrow Transplant*. [Epidemiology / Natural History]
Han SY (2025). [PMID: 41087182](https://pubmed.ncbi.nlm.nih.gov/41087182/). *Zhonghua Xue Ye Xue Za Zhi*. [Clinical Trial Publication]